Itaconate suppresses neonatal intestinal inflammation via metabolic reprogramming of M1 macrophage

Abstract

Background: Necrotizing enterocolitis (NEC) is a rapidly progressive and severe gastrointestinal disorder in neonates that is marked by an inflammatory cascade initiated by mechanisms that remain incompletely understood, resulting in intestinal necrosis and systemic infections. This study demonstrated that itaconate (ITA) exerts a protective effect in NEC by regulating macrophage reprogramming.

Methods: Changes in ITA expression were investigated using immunofluorescence staining and liquid chromatography-mass spectrometry, and their effect on immune cell differentiation was verified through single-cell sequencing. In vivo experiments were performed using ACOD1^−/- and ACOD1^fl/flLysM^cre NEC mouse models.

Results: We detected changes in ITA expression in clinical NEC samples and confirmed the effect of these changes on immune cell differentiation. In vivo experiments confirmed the therapeutic role of ITA in regulating macrophage differentiation in NEC, and we further investigated the mechanism by which ITA regulates macrophage metabolic reprogramming. The depletion of ITA in NEC correlates with an increased frequency of pro-inflammatory macrophage polarization, thereby exacerbating intestinal inflammatory injury. Importantly, our in vivo experiments revealed that treatment with 4-octyl itaconate (4OI) significantly mitigated intestinal symptoms associated with NEC in murine models. Mechanistic investigations showed that 4OI effectively suppressed M1 macrophage polarization by rescuing mitochondrial function and upregulating oxidative phosphorylation in macrophages.

Conclusions: Our results highlight ITA as a metabolic checkpoint of macrophage differentiation in NEC and suggest the therapeutic efficacy of 4OI in NEC.

Keywords

itaconate / macrophage / metabolic reprogramming / necrotizing enterocolitis / oxidative phosphorylation

References

[1] Nino DF, Sodhi CP, Hackam DJ. Necrotizing enterocolitis: new insights into pathogenesis and mechanisms. Nat Rev Gastroenterol Hepatol. 2016; 13(10): 590-600.

[2] Neu J, Walker WA. Necrotizing enterocolitis. N Engl J Med. 2011; 364(3): 255-264.

[3] Blakely ML, Tyson JE, Lally KP, et al. Initial Laparotomy versus peritoneal drainage in extremely low birthweight infants with surgical necrotizing enterocolitis or isolated intestinal perforation: a multicenter randomized clinical trial. Ann Surg. 2021; 274(4): e370-e380.

[4] Cao X, Zhang L, Jiang S, et al. Epidemiology of necrotizing enterocolitis in preterm infants in China: a multicenter cohort study from 2015 to 2018. J Pediatr Surg. 2022; 57(3): 382-386.

[5] Cho SX, Rudloff I, Lao JC, et al. Characterization of the pathoimmunology of necrotizing enterocolitis reveals novel therapeutic opportunities. Nat Commun. 2020; 11(1): 5794.

[6] Wei J, Meng Z, Li Z, Dang D, Wu H. New insights into intestinal macrophages in necrotizing enterocolitis: the multi-functional role and promising therapeutic application. Front Immunol. 2023; 14: 1261010.

[7] Kim JE, Li B, Fei L, et al. Gut microbiota promotes stem cell differentiation through macrophage and mesenchymal niches in early postnatal development. Immunity. 2022; 55(12): 2300-2317.

[8] Faas M, Ipseiz N, Ackermann J, et al. IL-33-induced metabolic reprogramming controls the differentiation of alternatively activated macrophages and the resolution of inflammation. Immunity. 2021; 54(11): 2531-2546.

[9] Jia N, Gao Y, Li M, et al. Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms. Signal Transduct Target Ther. 2023; 8(1): 280.

[10] Pan X, Zhu Q, Pan LL, Sun J. Macrophage immunometabolism in inflammatory bowel diseases: from pathogenesis to therapy. Pharmacol Ther. 2022; 238: 108176.

[11] Li M, Yang Y, Xiong L, Jiang P, Wang J, Li C. Metabolism, metabolites, and macrophages in cancer. J Hematol Oncol. 2023; 16(1): 80.

[12] Michelucci A, Cordes T, Ghelfi J, et al. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production. Proc Natl Acad Sci U S A. 2013; 110(19): 7820-7825.

[13] Peace CG, O'Neill LA. The role of itaconate in host defense and inflammation. J Clin Invest. 2022; 132(2): e148548.

[14] Wu R, Chen F, Wang N, Tang D, Kang R. ACOD1 in immunometabolism and disease. Cell Mol Immunol. 2020; 17(8): 822-833.

[15] Liu C, Fu C, Sun Y, et al. Itaconic acid regulation of TFEB-mediated autophagy flux alleviates hyperoxia-induced bronchopulmonary dysplasia. Redox Biol. 2024; 72: 103115.

[16] Swain A, Bambouskova M, Kim H, et al. Comparative evaluation of itaconate and its derivatives reveals divergent inflammasome and type I interferon regulation in macrophages. Nat Metab. 2020; 2(7): 594-602.

[17] Cordes T, Lucas A, Divakaruni AS, Murphy AN, Cabrales P, Metallo CM. Itaconate modulates tricarboxylic acid and redox metabolism to mitigate reperfusion injury. Mol Metab. 2020; 32: 122-135.

[18] Tomlinson KL, Riquelme SA, Baskota SU, et al. Staphylococcus aureus stimulates neutrophil itaconate production that suppresses the oxidative burst. Cell Rep. 2023; 42(2): 112064.

[19] Ye D, Wang P, Chen LL, Guan KL, Xiong Y. Itaconate in host inflammation and defense. Trends Endocrinol Metab. 2024; 35(7): 586-606.

[20] Chen B, Liu Y, Luo S, et al. Itaconic acid ameliorates necrotizing enterocolitis through the TFEB-mediated autophagy-lysosomal pathway. Free Radic Biol Med. 2025; 226: 251-265.

[21] Du L, Lin L, Li Q, et al. IGF-2 preprograms maturing macrophages to acquire oxidative phosphorylation-dependent anti-inflammatory properties. Cell Metab. 2019; 29(6): 1363-1375.

[22] Gershner GH, Hunter CJ. Redox chemistry: implications for necrotizing enterocolitis. Int J Mol Sci. 2024; 25(15): 8416.

[23] Ryan DG, O'Neill L. Krebs cycle reborn in macrophage immunometabolism. Annu Rev Immunol. 2020; 38: 289-313.

[24] Neurath MF. Strategies for targeting cytokines in inflammatory bowel disease. Nat Rev Immunol. 2024; 24(8): 559-576.

[25] Sampah M, Hackam DJ. Dysregulated mucosal immunity and associated pathogeneses in preterm neonates. Front Immunol. 2020; 11: 899.

[26] He YM, Li X, Perego M, et al. Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation. Nat Med. 2018; 24(2): 224-231.

[27] Wang S, Liu G, Li Y, Pan Y. Metabolic Reprogramming induces macrophage polarization in the tumor microenvironment. Front Immunol. 2022; 13: 840029.

[28] Mills EL, Ryan DG, Prag HA, et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature. 2018; 556(7699): 113-117.

[29] Yang W, Wang Y, Huang Y, et al. 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer. Biomed Pharmacother. 2023; 159: 114301.

[30] O'Neill LA, Pearce EJ. Immunometabolism governs dendritic cell and macrophage function. J Exp Med. 2016; 213(1): 15-23.

[31] Nolfi-Donegan D, Braganza A, Shiva S. Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biol. 2020; 37: 101674.

[32] Song J, Xiao L, Zhang Z, et al. Effects of reactive oxygen species and mitochondrial dysfunction on reproductive aging. Front Cell Dev Biol. 2024; 12: 1347286.

[33] Nemeth B, Doczi J, Csete D, et al. Abolition of mitochondrial substrate-level phosphorylation by itaconic acid produced by LPS-induced Irg1 expression in cells of murine macrophage lineage. Faseb J. 2016; 30(1): 286-300.

[34] Kachler K, Andreev D, Thapa S, et al. Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis. Ann Rheum Dis. 2024; 83(12): 1691-1706.

[35] Kim HW, Yu AR, Lee JW, et al. Aconitate Decarboxylase 1 deficiency exacerbates mouse colitis induced by dextran sodium sulfate. Int J Mol Sci. 2022; 23(8): 4392.

[36] Yang Y, Li Y, Yang W, et al. Protecting effects of 4-octyl itaconate on neonatal hypoxic-ischemic encephalopathy via Nrf2 pathway in astrocytes. J Neuroinflammation. 2024; 21(1): 132.

[37] Zhao N, Yi M, Zhang LJ, Zhang QX, Yang L. 4-Octyl Itaconate Attenuates neuroinflammation in experimental autoimmune encephalomyelitis via regulating microglia. Inflammation. 2025; 48(1): 151-164.

[38] Yang J, Duan C, Wang P, et al. 4-Octyl Itaconate Alleviates myocardial ischemia-reperfusion injury through promoting angiogenesis via ERK signaling activation. Adv Sci (Weinh). 2025; 12(10): e2411554.

[39] Liao ST, Han C, Xu DQ, Fu XW, Wang JS, Kong LY. 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to exert anti-inflammatory effects. Nat Commun. 2019; 10(1): 5091.

[40] Casati SR, Cervia D, Roux-Biejat P, Moscheni C, Perrotta C, De Palma C. Mitochondria and reactive oxygen species: the therapeutic balance of powers for duchenne muscular dystrophy. Cells. 2024; 13(7): 574.

[41] Addabbo F, Montagnani M, Goligorsky MS. Mitochondria and reactive oxygen species. Hypertension. 2009; 53(6): 885-892.

[42] Skwarski M, McGowan DR, Belcher E, et al. Mitochondrial inhibitor atovaquone increases tumor oxygenation and inhibits hypoxic gene expression in patients with non-small cell lung cancer. Clin Cancer Res. 2021; 27(9): 2459-2469.

[43] Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978; 187(1): 1-7.

[44] Luo S, Zeng Y, Chen B, et al. Vitamin E and GPX4 cooperatively protect treg cells from ferroptosis and alleviate intestinal inflammatory damage in necrotizing enterocolitis. Redox Biol. 2024; 75: 103303.

[45] Wan X, Xie B, Sun H, et al. Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis. Cancer Cell Int. 2022; 22(1): 83.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.